MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Aclaris Therapeutics Inc

Închisă

1.49 -2.61

Rezumat

Modificarea prețului

24h

Curent

Minim

1.47

Maxim

1.58

Indicatori cheie

By Trading Economics

Venit

-89M

-97M

Vânzări

4.9M

9.2M

EPS

-1.01

Marjă de profit

-1,048.225

Angajați

61

EBITDA

-4.4M

-14M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+500.65% upside

Dividende

By Dow Jones

Următoarele câștiguri

6 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-37M

173M

Deschiderea anterioară

4.1

Închiderea anterioară

1.49

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

Aclaris Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

16 iul. 2024, 20:04 UTC

Achiziții, Fuziuni, Preluări

Aclaris Therapeutics Received $26.5 M Upfront Plus Is Eligible for Up to $5M in Milestones >ACRS

16 iul. 2024, 20:03 UTC

Achiziții, Fuziuni, Preluări

Aclaris Sells Portion of Future Royalty Payments and Milestones From Eli Lilly on Sales of OLUMIANT for Alopecia Areata to OMERS

Comparație

Modificare preț

Aclaris Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

500.65% sus

Prognoză pe 12 luni

Medie 9.25 USD  500.65%

Maxim 15 USD

Minim 2 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAclaris Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

5 ratings

4

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

1.53 / 1.62Suport & Rezistență

Termen scurt

Bullish Evidence

Termen mediu

Bearish Evidence

Termen lung

Strong Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Aclaris Therapeutics Inc

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.